Document is current
Any future updates will be listed below
-
Authors
Jansen, Y. https://orcid.org/0000-0002-8322-9841
van der Veldt, A. A. M. https://orcid.org/0000-0003-0446-1907
Awada, G. https://orcid.org/0000-0001-9535-0430
Neyns, B. https://orcid.org/0000-0003-0658-5903
- License Information
-
More Information
Article History
Accepted: 28 January 2022
First Online: 26 March 2022
Declarations
:
: Y. Jansen: travel, accommodations, and expenses—MSD Oncology, Novartis, BMS.A. A. M. van der Veldt MD, PhD: advisory/consultancy (paid to the institute): BMS, Eisai, Ipsen, MSD, Merck, Novartis, Pfizer, Roche, Pierre Fabre, Sanofi.G. Awada: consulting or advisory role—Novartis; honoraria—Novartis, Biocartis; research funding—Novartis (institutional), Stichting tegen Kanker (institutional), Kom op tegen Kanker (institutional); travel, accommodations, and expenses—Astellas Pharma, MSD Oncology, Novartis.B. Neyns: consulting or advisory role—Roche, Bristol-Myers Squibb, MSD Oncology, Novartis; honoraria—Roche, Bristol-Myers Squibb, MSD Oncology, Novartis; research funding—Pfizer (institutional), Novartis (institutional), Roche (institutional), Merck-Serono (institutional).
: This article does not contain any studies with human or animal subjects performed by any of the authors.
